Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany.
Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
J Pharm Sci. 2020 Jan;109(1):505-514. doi: 10.1016/j.xphs.2019.10.061. Epub 2019 Nov 2.
Subvisible particles are a critical quality attribute of pharmaceutical products. The reliability of particle quantitation increases with the number of particles in the analyzed sample volume. However, for analyses of low-volume drug products, such as ophthalmic products for intravitreal injection or biopharmaceuticals in general, sample volumes as small as possible should be used to avoid pooling and consequently, the contamination with foreign particles. The aim of our study was to evaluate the variability of particle concentrations obtained by light obscuration measurements to define the minimum required analyzed sample volume to achieve statistically meaningful results by using conditions that are practically feasible. Statistical evaluation suggests that for particle concentrations close to a predefined limit, large sample volumes (a multiple of typical intravitreal product volumes) would be required for a high probability to correctly classify samples with respect to the predefined limit. Below a minimum analyzed volume, even a measurement result of 0 particles does not allow to conclude compliance with the respective particle concentration limit with sufficient certainty. A small analyzed volume could be justified as long as the measurement uncertainty remains acceptable compared with the predefined limit.
亚可见颗粒是药物产品的一个关键质量属性。随着分析样品体积中颗粒数量的增加,颗粒定量的可靠性也会提高。然而,对于低体积药物产品的分析,如用于玻璃体内注射的眼科产品或一般的生物制药产品,应尽可能使用最小体积的样品,以避免混合,从而避免混入外来颗粒。我们的研究目的是评估光遮挡测量得到的颗粒浓度的可变性,以确定通过使用实际可行的条件获得具有统计学意义结果所需的最小分析样品体积。统计评估表明,对于接近预定限值的颗粒浓度,为了有很大的可能性正确地将样品分类为符合预定限值,需要使用大体积的样品(典型玻璃体内产品体积的倍数)。在最小分析体积以下,即使测量结果为 0 个颗粒,也不能确定符合相应的颗粒浓度限值。只要测量不确定度相对于预定限值仍可接受,小体积的分析就可以被证明是合理的。